Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.
Actively Recruiting
Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.
Actively Recruiting
Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.